The impact of the histological classification of ampullary carcinomas on long-term outcomes after pancreaticoduodenectomy: a single tertiary referral center evaluation.
Ampullary carcinoma
Disease-free survival
Histotype
Long-term outcomes
Overall survival
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
26
01
2022
accepted:
18
05
2022
pubmed:
8
6
2022
medline:
10
11
2022
entrez:
7
6
2022
Statut:
ppublish
Résumé
Ampullary carcinomas (ACs) are classified as pancreatobiliary (Pb-AC), intestinal (Int-AC), or mixed (Mixed-AC). The influencing role of AC subtypes on long-term outcomes is still matter of debate. Aim of this study is to evaluate the prognostic role of the three histological variants on the overall (OS) and disease-free survival (DFS) after pancreaticoduodenectomy(PD). All PDs for AC between 2004 and 2020 were included. Patients were classified according to the histological feature in Pb-AC, Int-AC, and Mixed-AC. Five-year OS and DFS were compared among the subtypes. Additionally, the prognostic role of the histological classification on OS and DFS was evaluated. Fifty-six (48.7%) Pb-ACs, 53 (46.1%) Int-ACs, and 6 (5.2%) Mixed-ACs were evaluated. A poorer 5-year OS was evidenced for the Pb-AC group (54.1%) as compared to the Int-AC cohort (80.7%) (p = 0.03), but similar to the Mixed-AC population (33%) (p = 0.45). Pb-AC presented a worse 5-year DFS (42.3%) in comparison to the Int-AC (74.8%) (p = 0.002), while no difference was evidenced in comparison to the Mixed-AC (16.7%) (p = 0.51). At the multivariate analysis, the Pb-/Mixed-AC histotype was recognized as negative prognostic factor for both OS (OR: 2.29, CI: 1.05-4.98; p = 0.04) and DFS (OR: 2.17, CI: 1-4.33; p = 0.02). Histological subtypes of AC play a relevant role in long-term outcomes after PD. Pb-ACs and Mixed-ACs show a more aggressive tumor biology and a consequent worse survival as compared to the Int-AC subtype.
Identifiants
pubmed: 35670860
doi: 10.1007/s00423-022-02563-z
pii: 10.1007/s00423-022-02563-z
pmc: PMC9640450
doi:
Substances chimiques
Lead
2P299V784P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2811-2821Informations de copyright
© 2022. The Author(s).
Références
Albores-Saavedra J, Schwartz AM, Batich K, Henson DE (2009) Cancers of the ampulla of Vater: demographics, morphology, and survival based on 5,625 cases from the SEER Program. J Surg Oncol 100:598–605. https://doi.org/10.1002/jso.21374
doi: 10.1002/jso.21374
pubmed: 19697352
Kimura W, Futakawa N, Yamagata S et al (1994) Different clinicopathologic findings in two histologic types of carcinoma of papilla of Vater. Japanese J Cancer Res 85:161–166. https://doi.org/10.1111/j.1349-7006.1994.tb02077.x
doi: 10.1111/j.1349-7006.1994.tb02077.x
Albores-Saavedra J, Henson DE, Klimstra DS (2015) Tumors of the gallbladder, extrahepatic bile ducts, and Vaterian system. Atlas of tumor pathology, Washington DC; Armed Forces Inst. of Pathology. Fascicle 23
Fischer HP, Zhou H (2004) Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg 11:301–309
doi: 10.1007/s00534-004-0898-3
pubmed: 15549428
Ang DC, Shia J, Tang LH et al (2014) The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of Vater. Am J Surg Pathol 38. https://doi.org/10.1097/PAS.0000000000000230
Kim WS, Choi DW, Choi SH et al (2012) Clinical significance of pathologic subtype in curatively resected ampulla of Vater cancer. J Surg Oncol 105:266–272. https://doi.org/10.1002/jso.22090
doi: 10.1002/jso.22090
pubmed: 21882202
Winter JM, Cameron JL, Olino K et al (2010) Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg 14:379–87. https://doi.org/10.1007/s11605-009-1080-7
doi: 10.1007/s11605-009-1080-7
pubmed: 19911239
Zhou H, Schaefer N, Wolff M, Fischer HP (2004) Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 28:875–82. https://doi.org/10.1097/00000478-200407000-00005
doi: 10.1097/00000478-200407000-00005
pubmed: 15223956
Riall TS, Cameron JL, Lillemoe KD et al (2006) Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 140:764–72. https://doi.org/10.1016/j.surg.2006.04.006
doi: 10.1016/j.surg.2006.04.006
pubmed: 17084719
Hsu HP, Yang TM, Hsieh YH et al (2007) Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 14:50–60. https://doi.org/10.1245/s10434-006-9136-3
doi: 10.1245/s10434-006-9136-3
pubmed: 17054003
Chang DK, Jamieson NB, Johns AL et al (2013) Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of Vater. J Clin Oncol 31:1348–56. https://doi.org/10.1200/JCO.2012.46.8868
doi: 10.1200/JCO.2012.46.8868
pubmed: 23439753
Schiergens TS, Reu S, Neumann J et al (2015) Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater. Surg (United States) 158:151–61. https://doi.org/10.1016/j.surg.2015.02.001
doi: 10.1016/j.surg.2015.02.001
Zimmermann C, Wolk S, Aust DE et al (2019) The pathohistological subtype strongly predicts survival in patients with ampullary carcinoma. Sci Rep 9:1–8
doi: 10.1038/s41598-019-49179-w
Zhou Y, Li D, Wu L, Si X (2017) The histopathologic type predicts survival of patients with ampullary carcinoma after resection: a meta-analysis. Pancreatology 17:273–278
doi: 10.1016/j.pan.2017.01.007
pubmed: 28131524
Ecker BL, Vollmer CM, Behrman SW et al (2019) Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. JAMA Surg 154:706–714. https://doi.org/10.1001/jamasurg.2019.1170
doi: 10.1001/jamasurg.2019.1170
pubmed: 31141112
pmcid: 6547142
Al Abbas AI, Falvello V, Zenati M et al (2020) Impact of adjuvant chemotherapy regimen on survival outcomes in immunohistochemical subtypes of ampullary carcinoma. J Surg Oncol 121:322–329
doi: 10.1002/jso.25808
Jin Z, Hartgers ML, Sanhueza CT et al (2018) Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur J Surg Oncol 44:677–683
doi: 10.1016/j.ejso.2018.02.008
pubmed: 29506768
de Paiva Haddad LB, Patzina RA, Penteado S et al (2010) Lymph node involvement and not the histophatologic subtype is correlated with outcome after resection of adenocarcinoma of the ampulla of vater. J Gastrointest Surg 14:719–728
doi: 10.1007/s11605-010-1156-4
pubmed: 20107918
Quero G, Fiorillo C, Menghi R et al (2020) Total mesopancreas excision for periampullary malignancy: a single-center propensity score-matched comparison of long-term outcomes. Langenbeck’s Arch Surg 405:303–312. https://doi.org/10.1007/s00423-020-01873-4
doi: 10.1007/s00423-020-01873-4
Tol JAMG, Gouma DJ, Bassi C et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surg (United States) 156:591–600. https://doi.org/10.1016/j.surg.2014.06.016
doi: 10.1016/j.surg.2014.06.016
Clavien PA, Barkun J, De Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250:187–96
doi: 10.1097/SLA.0b013e3181b13ca2
pubmed: 19638912
Bassi C, Marchegiani G, Dervenis C et al (2017) The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 years after. Surg (United States) 161:584–591
Infirmary GR (2013) Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct May 2010, 2nd edition. RCPath
Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182
doi: 10.1111/his.13975
pubmed: 31433515
Quero G, Fiorillo C, De Sio D et al (2021) The role of mesopancreas excision for ampullary carcinomas: a single center propensity-score matched analysis. HPB. https://doi.org/10.1016/j.hpb.2021.03.011
doi: 10.1016/j.hpb.2021.03.011
pubmed: 34654621
Neoptolemos JP, Talbot IC, Shaw DC, Carr-Locke DL (1988) Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness. Cancer 61:1403–7. https://doi.org/10.1002/1097-0142(19880401)61:7<1403::AID-CNCR2820610721>3.0.CO;2-S
doi: 10.1002/1097-0142(19880401)61:7<1403::AID-CNCR2820610721>3.0.CO;2-S
pubmed: 2449947
Roh YH, Kim YH, Lee HW et al (2007) The clinicopathologic and immunohistochemical characteristics of ampulla of Vater carcinoma: the intestinal type is associated with a better prognosis. Hepatogastroenterology 54:1641–4
pubmed: 18019683
Nappo G, Galvanin J, Gentile D et al (2021) Long-term outcomes after pancreatoduodenectomy for ampullary cancer: the influence of the histological subtypes and comparison with the other periampullary neoplasms. Pancreatology 21:950–956. https://doi.org/10.1016/j.pan.2021.03.005
doi: 10.1016/j.pan.2021.03.005
pubmed: 33795194
Westgaard A, Pomianowska E, Clausen OPF, Gladhaug IP (2013) Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies? Ann Surg Oncol 20:430–9. https://doi.org/10.1245/s10434-012-2603-0
doi: 10.1245/s10434-012-2603-0
pubmed: 22956064
Howe JR, Klimstra DS, Moccia RD et al (1998) Factors predictive of survival in ampullary carcinoma. Ann Surg 228:87–94. https://doi.org/10.1097/00000658-199807000-00013
doi: 10.1097/00000658-199807000-00013
pubmed: 9671071
pmcid: 1191432
De Castro SMM, Van Heek NT, Kuhlmann KFD et al (2004) Surgical management of neoplasms of the ampulla of Vater: local resection or pancreatoduodenectomy and prognostic factors for survival. Surgery 136:994–1002. https://doi.org/10.1016/j.surg.2004.03.010
doi: 10.1016/j.surg.2004.03.010
pubmed: 15523392
Vilhordo DW, Gregório C, Valentini DF et al (2021) Prognostic factors of long-term survival following radical resection for ampullary carcinoma. J Gastrointest Cancer 52. https://doi.org/10.1007/s12029-020-00479-9
Williams JL, Chan CK, Toste PA et al (2017) Association of histopathologic phenotype of periampullary adenocarcinomas with survival. JAMA Surgery 152:82–88
doi: 10.1001/jamasurg.2016.3466
pubmed: 27732711
Carter JT, Grenert JP, Rubenstein L et al (2008) Tumors of the ampulla of Vater: histopathologic classification and predictors of survival. J Am Coll Surg 207:210–8. https://doi.org/10.1016/j.jamcollsurg.2008.01.028
doi: 10.1016/j.jamcollsurg.2008.01.028
pubmed: 18656049
Talamini MA, Moesinger RC, Pitt HA et al (1997) Adenocarcinoma of the ampulla of Vater: a 28-year experience. Ann Surg 225:590–9. https://doi.org/10.1097/00000658-199705000-00015
doi: 10.1097/00000658-199705000-00015
pubmed: 9193186
pmcid: 1190801
Beger HG, Treitschke F, Gansauge F et al (1999) Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 134:526–32. https://doi.org/10.1001/archsurg.134.5.526
doi: 10.1001/archsurg.134.5.526
pubmed: 10323425
Neoptolemos JP, Moore MJ, Cox TF et al (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA - J Am Med Assoc 308:147–56. https://doi.org/10.1001/jama.2012.7352
doi: 10.1001/jama.2012.7352
Bhatia S, Miller RC, Haddock MG et al (2006) Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 66. https://doi.org/10.1016/j.ijrobp.2006.04.018
Nassour I, Hynan LS, Christie A et al (2018) Association of adjuvant therapy with improved survival in ampullary cancer: a national cohort study. J Gastrointest Surg 22. https://doi.org/10.1007/s11605-017-3624-6